PMID- 36323544
OWN - NLM
STAT- MEDLINE
DCOM- 20221107
LR  - 20221107
IS  - 0529-5807 (Print)
IS  - 0529-5807 (Linking)
VI  - 51
IP  - 11
DP  - 2022 Nov 8
TI  - [CIC-rearranged sarcoma with rhabdoid features: a clinicopathological analysis].
PG  - 1141-1146
LID - 10.3760/cma.j.cn112151-20220831-00752 [doi]
AB  - Objective: To investigate the histopathologic, immunohistochemical, molecular 
      genetic characteristics of CIC-rearranged sarcoma (CRS) with rhabdoid features. 
      Methods: The clinical and pathologic data of two cases of CRS diagnosed between 
      2019 and 2021 at the Department of Pathology, Jiangsu Province Hospital were 
      analyzed. Immunohistochemical study and fluorescence in situ hybridization (FISH) 
      were performed. The relevant literature was reviewed. Results: Both patients were 
      female, one was 58 years old, with tumor located in left thigh; the other was 43 
      years old, with tumor located in left pelvic cavity. Microscopically, both tumors 
      were composed of small to medium-sized round, oval cells, arranged in nodules or 
      sheets. The tumor cells showed irregular nuclear outline, coarse chromatin with 
      prominent nucleoli and brisk mitotic activity. Both cases showed rhabdoid 
      phenotype with myxoid stromal changes. Immunohistochemically, both cases were 
      positive for CD99 and c-myc. High WT1 reactivity was seen in classic area, with 
      low reactivity in rhabdoid area. There was no INI1 lost in both cases. Both were 
      negative for NKX2.2 and NKX3.1. By FISH both cases demonstrated convincing 
      break-apart signals of CIC gene. One patient died of disease after 1 month, and 
      the other died of disease after 3 months. Conclusions: CRS is a small round cell 
      undifferentiated sarcoma of the bone and soft tissue defined by molecular genetic 
      characteristics, and may show atypical morphologic and immunophenotypic 
      characteristics such as rhabdoid features. A correct understanding of its rare 
      morphologic and immunophenotypic characteristics, combined with molecular 
      pathologic detection, is conducive to correct diagnosis.
FAU - Pan, B J
AU  - Pan BJ
AD  - Department of Pathology, Jiangsu Province People's Hospital (the First Affiliated 
      Hospital of Nanjing Medical University), Nanjing 210029, China.
FAU - Gong, Q X
AU  - Gong QX
AD  - Department of Pathology, Jiangsu Province People's Hospital (the First Affiliated 
      Hospital of Nanjing Medical University), Nanjing 210029, China.
FAU - Li, H
AU  - Li H
AD  - Department of Pathology, Jiangsu Province People's Hospital (the First Affiliated 
      Hospital of Nanjing Medical University), Nanjing 210029, China.
FAU - Ma, S Y
AU  - Ma SY
AD  - Department of Pathology, Jiangsu Province People's Hospital (the First Affiliated 
      Hospital of Nanjing Medical University), Nanjing 210029, China.
FAU - Song, G X
AU  - Song GX
AD  - Department of Pathology, Jiangsu Province People's Hospital (the First Affiliated 
      Hospital of Nanjing Medical University), Nanjing 210029, China.
FAU - Li, X
AU  - Li X
AD  - Department of Pathology, Jiangsu Province People's Hospital (the First Affiliated 
      Hospital of Nanjing Medical University), Nanjing 210029, China.
FAU - Ding, Y
AU  - Ding Y
AD  - Department of Pathology, Jiangsu Province People's Hospital (the First Affiliated 
      Hospital of Nanjing Medical University), Nanjing 210029, China.
FAU - Fan, Q H
AU  - Fan QH
AD  - Department of Pathology, Jiangsu Province People's Hospital (the First Affiliated 
      Hospital of Nanjing Medical University), Nanjing 210029, China.
FAU - Zhang, Z H
AU  - Zhang ZH
AD  - Department of Pathology, Jiangsu Province People's Hospital (the First Affiliated 
      Hospital of Nanjing Medical University), Nanjing 210029, China.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Bing Li Xue Za Zhi
JT  - Zhonghua bing li xue za zhi = Chinese journal of pathology
JID - 0005331
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Female
MH  - Humans
MH  - Male
MH  - Biomarkers, Tumor/genetics/analysis
MH  - In Situ Hybridization, Fluorescence
MH  - *Sarcoma/pathology
MH  - *Sarcoma, Small Cell/diagnosis/genetics/pathology
MH  - Transcription Factors/genetics
MH  - Rhabdoid Tumor/diagnosis/genetics/pathology
EDAT- 2022/11/03 06:00
MHDA- 2022/11/05 06:00
CRDT- 2022/11/02 22:38
PHST- 2022/11/02 22:38 [entrez]
PHST- 2022/11/03 06:00 [pubmed]
PHST- 2022/11/05 06:00 [medline]
AID - 10.3760/cma.j.cn112151-20220831-00752 [doi]
PST - ppublish
SO  - Zhonghua Bing Li Xue Za Zhi. 2022 Nov 8;51(11):1141-1146. doi: 
      10.3760/cma.j.cn112151-20220831-00752.